Company Profile
Company ProfileHome > Company Profile

  WEGO HOLDING COMPANY LIMITED (“WEGO”) established in March 1988, and the major business of WEGO focus on medical devices and pharmaceuticals. In addition, WEGO develops some other business such as real estate, investment and so on. WEGO has 9 industry groups and more than 30 subsidiaries. The main products of WEGO are infusion set& syringe, blood transfusion equipment, heart stent & intracardiac consumable,IV catheter & special needle, blood purification equipment and consumables, orthopedic material, operation room equipment and accessories, wound care product, minimally invasive instrument and equipment, ICU product and accessories, high-capacity injection and pharmaceutical, renal product, biological diagnostic reagent, PVC & non-PVC material and so on. WEGO produces more than 30 series, 400 categories and 40,000 specifications products, and has become one of the most reliable suppliers of medical system in the word. At the same time, WEGO energetically takes part in healthcare service and provides renal dialysis service. WEGO’s holding subsidiary ---SHANDONG WEIGAO GROUP MEDICAL POLYMER CO., LIMITED is listed in Hong Kong.

     Shandong WEGO Prefills Pharmaceutical Packaging Co.,Ltd is a subsidiary company of Shandong Weigao Group Medical Polymer Company Limited. In the year of 2004, the company introduced the most advanced producing lines and producing technologies of prefillable syringes from Germany .With the first class manufacturing machines and producing technologies in the world, the production capacity of prefillable syringes covering various specifications come up to 300 million pieces per year.  The company consistently works hard on development & research;meanwhile we are eager to achieve perfect product quality which ensures the prefillable syringes can meet all kinds of strict requirements of customers. With the concept of supplying products of high quality, safety, cost effectiveness and consistent innovation, and with perfect services, we take our effort to become a trustworthy pharmaceutical enterprise.  

    In the past 20 years, the Group rooted with the spirit of “development, innovation, pragmatism and consolidation”. It has based its operations on developing high technology and profitable new medical devices, while enhancing product quality and reinforcing scientific management skills. Its development strategy of focusing on the needs of the public and prioritizing science and technology research has ensured a speedy, sustainable and wholesome development of the Group. It has instituted ERP, JIT and KPI management system firstly in the industry and passed the certification of ISO9001:2000, ISO13485:2003, CE, China Quality Certification Center for Medical Devices, and China Compulsory Certification, etc. Some products achieve registration of FDA 510K from Food and Drug Association (FDA).The award accredited to testing and inspection center of the company is also the only certification issued by China National Accreditation Board for Lab oratories in industry.
       Weigao will continue to strive without reserve for the scientific development, and our mission is to “work with physicians to create healthy life for people in future”. Weigao will continue to improve and adjust the business structure, products mix and organizational structure. Gradually transforming from a domestic manufacturer to an internationally competitive, leading in Asia, and respectable conglomerate is our goal. Weigao, as a leading medical device company, continues to create and sustain a high level of performance in medical device products and pharmaceuticals. Weigao is well-positioned to continuing serving the medical community and improve people's health for generations to come. 

© Weigao group 2020 鲁ICP备14005520号-8